RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst
CG Oncology, Inc. (NASDAQ:CGON) is one of the best performing healthcare stocks so far in 2026. RBC Capital lifted the price target on CG Oncology, Inc.
Cg Oncology Inc. (CGON)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Decheng Capital Min Cui | 6,371,669 | $431,234,558 | 65.21% | |
| 2. | EcoR1 Capital Oleg Nodelman | 1,102,000 | $74,583,360 | +43% | 3.17% |
| 3. | Driehaus Capital Richard Driehaus | 999,623 | $67,654,485 | 0.5% | |
| 4. | Braidwell LP Alex Karnal | 984,783 | $66,650,113 | -48% | 2.22% |
| 5. | OrbiMed Advisors Samuel Isaly | 948,267 | $64,178,711 | -38% | 1.27% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $33.00 | 1,515,151 | $49,999,983.00 | 1,515,151 | 2025-09-11 | Filing | |
| $19.00 | 400,000 | $7,600,000.00 | 4,958,810 | 2024-01-29 | Filing | |
| $19.00 | 1,315 | $24,985.00 | 1,315 | 2024-01-29 | Filing | |
| $19.00 | 2,000 | $38,000.00 | 2,000 | 2024-01-29 | Filing | |
| $19.00 | 263,157 | $4,999,983.00 | 613,928 | 2024-01-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $73.01 | 15,600 | $1,138,956.00 | 0 | 2026-04-17 | Filing | |
| $63.50 | 1,310 | $83,185.00 | 0 | 2026-03-16 | Filing | |
| $63.50 | 654 | $41,529.00 | 0 | 2026-03-16 | Filing | |
| $52.99 | 10,491 | $555,918.09 | 0 | 2026-01-09 | Filing | |
| $44.16 | 654 | $28,880.64 | 0 | 2026-01-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,984,808 | $472,731,805 | 4.7% | |
| 2. | 5,371,232 | $363,524,981 | 0.07% | |
| 3. | 5,064,180 | $342,743,702 | 0.01% | |
| 4. | 3,764,844 | $254,804,642 | 0.01% | |
| 5. | 3,670,206 | $248,399,542 | 7.11% |
News See All
10 Best Performing Healthcare Stocks So Far in 2026
She was of the view that the backdrop at present is featuring geopolitical tensions, Fed policy uncertainty, inflation concerns, and still, it is incredible that the stock market is at record highs.
CG Oncology (CGON) Rallied on Pivotal Clinical Results
Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter is available to download here.
H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating
On February 27, 2026, H.C. Wainwright raised the firm's price target on CG Oncology, Inc. (NASDAQ:CGON) to $80 from $75 and maintained a Buy rating on the shares.
10 Fastest Growing NASDAQ Stocks to Buy
High growth stocks have once again taken center stage, and major asset managers argue that earnings momentum remains the decisive factor. In its 2026 Year-Ahead Investment Outlook, J.P.
CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities
CG Oncology Inc. (NASDAQ:CGON) is one of the best 52-week high stocks to buy right now. On November 24, analysts at Truist Securities initiated coverage of CG Oncology Inc.
12 Best 52-Week High Stocks to Buy Right Now
All three major US indices are poised to end the year near record highs in what is turning out to be a blockbuster year for stocks.
CG Oncology (CGON) Gets Initiated With a Buy at Guggenheim
CG Oncology, Inc. (NASDAQ:CGON) is one of the best healthcare stocks with the highest upside. On October 7, CG Oncology, Inc.
9 Best Healthcare Stocks with the Highest Upside
Talking about how people are feeling the impact of the shutdown, Dr.
Guggenheim Initiates CG Oncology (CGON) Coverage with $90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene
CG Oncology Inc. (NASDAQ:CGON) is one of the best hot stocks to invest in. On October 8, Guggenheim analyst Brad Canino initiated coverage of CG Oncology with a Buy rating and $90 price target.
Hedge Fund Resource Center